New version of Vermont Rx data law in court
A renewed attempt to block physicians' prescribing data from being gathered for the use of pharmaceutical firms has been initiated in the northeastern US state of Vermont. Previous attempts to introduce such restrictions have failed in nearby New Hampshire and Maine (Marketletters passim).
Julie Brill, an Assistant Attorney General for the state, told the Boston.com web site that datamining restrictions were "one part of a larger effort by the state to ensure that marketing that goes on with respect to pharmaceutical products is appropriate and...to protect the privacy concerns prescribers have."
In an attempt to overcome a legal challenge by health care information providers IMS Health, Wolters Kluwer Health (via its subsidiary Source Healthcare Analytics) and Verispan, the Vermont authorities have delayed the existing law's enactment to September 2008, instead of January 1 and re-drafted sections of the legislation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze